Canopy Growth Corporation · TSX:WEED
Canopy Growth — Investor Presentation (June 2025)
24 slides from Canopy Growth's investor presentation, June 2025
Slide 1: Investor Presentation June 2025
INVESTOR PRESENTATION June 2025
Slide 2: Disclaimers and Cautionary Statements: Forward-Looking Information (1/4)
DISCLAIMERS AND CAUTIONARY STATEMENTS Forward-Looking Information (1/4) Unless otherwise noted or the context indicates otherwise, references in this presentation (this “Presentation”) to the “Company,” “Canopy Growth,” “we,” “us” and “our” refer to Canopy Growth Corporation and its direct and indir
Slide 3: Disclaimers and Cautionary Statements: Forward-Looking Information (2/4)
DISCLAIMERS AND CAUTIONARY STATEMENTS Forward-Looking Information (2/4) the legalization of the use of cannabis for medical or adult-use in jurisdictions outside of Canada, the related timing and impact thereof and our intentions to participate in such markets, if and when such use is legalized; our
Slide 4: Disclaimers and Cautionary Statements: Forward-Looking Information (3/4)
DISCLAIMERS AND CAUTIONARY STATEMENTS Forward-Looking Information (3/4) By their nature, forward-looking statements are subject to inherent risks and uncertainties that may be general or specific and which give rise to the possibility that expectations, forecasts, predictions, projections or conclus
Slide 5: Disclaimers and Cautionary Statements: Forward-Looking Information (4/4)
DISCLAIMERS AND CAUTIONARY STATEMENTS Forward-Looking Information (4/4) Forward-looking statements are provided for the purposes of assisting the reader in understanding our financial performance, financial position and cash flows as of and for periods ended on certain dates and to present informati
Slide 6: Non-GAAP Measures
NON-GAAP MEASURES Adjusted EBITDA is a non-GAAP measure used by management that is not defined by U.S. GAAP and may not be comparable to similar measures presented by other companies. Management believes Adjusted EBITDA is a useful measure for investors because it provides meaningful and useful fina
Slide 7: Canopy Growth: Positioned for sustainable cannabis market leadership
Canopy Growth: Positioned for sustainable cannabis market leadership Cannabis centered Dedicated to unleashing the power of cannabis in key markets. Brand & Consumer-led Industry-leading brands and products rooted in consumer preferences. Global reach A $70B CAD market opportunity by 20281. Improvin
Slide 8: $70B+ Legal Cannabis Market Opportunity by 2028
$70b+ Legal CANNABIS MARKET OPPORTUNITY BY 2028 Driven by Gaining Consumer acceptance 1 $70 61.3 $60 57.3 53.2 $50 48.9 43.5 CAD $ Billions $40 $30 $20 $10 6.4 6.6 6.8 7.0 7.2 0.8 0.9 1.1 1.3 1.3 $- 2024 2025 2026 2027 2028 Canada USA Int'l (Germany, Poland, Czechia, ANZ) Includes German (med + rec)
Slide 9: Purpose-Built Structure to Unlock Value Across Core Markets
Dedicated to being a leader in the cannabis sector: Purpose-Built Structure to Unlock Value Across Core Markets Canopy Growth has implemented a new focused business structure designed to improve execution, drive margin expansion, and unlock value across its most promising commercial opportunities. E
Slide 10: Executing with Discipline Across Each Business
Dedicated to being a leader in the cannabis sector: Executing with Discipline Across Each Business Unified Global Simplified Canada Storz & Bickel Global Cannabis Medical Adult-Use CAN, GER, POL, AUS Operations Objectives Global Medical Cannabis Profitable Scale in Right product, right Uncontested Le
Slide 11: Focus in FY2026: Driving Growth Through Execution and Discipline
FOCUS IN FY2026: Driving Growth Through Execution and Discipline 1. Accelerate revenue growth in Global Medical through improved supply continuity and deeper market engagement. 2. Strengthen commercial execution and margin performance in Canada’s Adult-Use market by focusing on high-demand formats a
Slide 12: Canada Cannabis – Q4 & FY2025
CANADA CANNABIS – Q4 & FY2025 • Canada cannabis net revenue was $159MM in FY2025, representing a decline of 2% compared to FY2024. • Canada medical cannabis net revenue in FY2025 increased 16% compared to FY2024 driven primarily by an increase in the average size of medical orders placed by our cust
Slide 13: International Markets – Q4 & FY2025
INTERNATIONAL MARKETS - Q4 & FY2025 • International markets net revenue was $40MM in FY2025, representing a decrease of 4% over FY2024, with strong growth in Poland and Germany, offset by declines in Australia medical cannabis sales and a transition of our U.S. CBD business to Canopy USA, which was
Slide 14: Storz & Bickel – Q4 & FY2025
STORZ & BICKEL ® – Q4 & FY2025 • Storz & Bickel delivered net revenue in FY2025 of $73MM, representing a 4% increase over FY2024 driven by a full year of Venty sales. • Subsequent to the fiscal quarter end, Storz & Bickel introduced the VOLCANO CLASSIC 25 Years Edition to commemorate the 25th annive
Slide 15: Canopy USA Update
Canopy USA 1 UPDATE Canopy USA1 Operating Businesses Canopy USA1 Investment WANA2 - gummies Jetty3 - extracts ACREAGE4 - MSO TERRASCEND5 - MSO An innovative North American Authentic vape experience and Vertical integration from Vertical integration in in PA, NJ, cannabis edibles brand award-winning
Slide 16: Q4 & FY2025 Financial Results
Q4 & FY2025 FINANCIAL RESULTS
Slide 17: Q4 FY2025 Key Financial Highlights
Q4 FY2025 KEY FINANCIAL HIGHLIGHTS Canopy delivered Consolidated Net Revenue of $65 MM in Q4 FY2025, which is down 11% compared to Q4 of last year, (CDN in vs. Main drivers of revenue were: millions) Q4 FY2025 Q4 FY2024 FY2025 vs. FY2024 Canada medical cannabis revenue increased 13% compared to a
Slide 18: Revenue Performance by Channel
REVENUE PERFORMANCE BY CHANNEL1 vs. vs. (in millions of Canadian dollars, unaudited) Q4 FY2025 Q4 FY2024 FY2025 FY2024 Canada cannabis Canada adult-use cannabis2, 4 $20.4 (3%) $78.8 (15%) Canada medical cannabis3, 5 $20.0 13% $77.0 16% $40.4 4% $155.8 (2%) International markets cannabis6 $7.5 (35%)
Slide 19: Gross Margin Performance
GROSS MARGIN PERFORMANCE Drivers of Q4 FY2025 Gross Margin Year-over-Year Change By Consolidated Gross Margin Performance Reported Segment (+) The increase in Canada Cannabis segment driven primarily by Consolidated Canada Cannabis a mix shift to higher margin Canada medical cannabis sales. Gross Ma
Slide 20: Free Cash Flow and Debt
FREE CASH FLOW AND DEBT Free Cash Flow1 Total Debt Balance ($CAD’MM) ($CAD’MM) - 597 Q4 FY24 Q4 FY25 FY24 FY25 600 561 554 (23) (50) (36) 500 442 (100) 400 304 (150) 300 (177) 200 (200) 100 (250) (231) Q4 FY24 Q4 FY25 FY24 FY25 - Q4 FY24 Q1 FY25 Q2 FY25 Q3 FY25 Q4 FY25 • Free cash flow was an outflo
Slide 21: Appendix
APPENDIX
Slide 22: Adjusted EBITDA (Non-GAAP) Reconciliation
ADJUSTED EBITDA1 (NON-GAAP) RECONCILIATION
Slide 23: Free Cash Flow (Non-GAAP) Reconciliation
FREE CASH FLOW1 (NON-GAAP) RECONCILIATION
Slide 24: Thank You
THANK YOU 24